IDL Biotech Q1: First comment
In the first quarter, IDL reported sales and EBIT in line with our expectations. The company guides for a remarkable drop in net sales in Q2 due to effects of the corona crisis. We provide a short comment on the Q1 release and plan return with a research update within the next days.